Open Access 06-03-2025 | Osteoporosis | Review
PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis
Published in: Osteoporosis International
Login to get accessPlease log in to get access to this content
Appendix
Available only for authorised users
Literature
1.
go back to reference Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D (1997) Guidelines for diagnosis and management of osteoporosis. The European foundation for osteoporosis and bone disease. Osteoporos Int 7:390–406PubMedCrossRef
Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D (1997) Guidelines for diagnosis and management of osteoporosis. The European foundation for osteoporosis and bone disease. Osteoporos Int 7:390–406PubMedCrossRef
2.
go back to reference Kanis JA, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, McCloskey EV, Willers C, Borgstrom F (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 16:82PubMedPubMedCentralCrossRef
Kanis JA, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, McCloskey EV, Willers C, Borgstrom F (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 16:82PubMedPubMedCentralCrossRef
3.
go back to reference Kanis JA, McCloskey EV, Harvey NC, Cooper C, Rizzoli R, Dawson-Hughes B, Maggi S, Reginster JY (2022) Intervention thresholds and diagnostic thresholds in the management of osteoporosis. Aging Clin Exp Res 34:3155–3157PubMedPubMedCentralCrossRef
Kanis JA, McCloskey EV, Harvey NC, Cooper C, Rizzoli R, Dawson-Hughes B, Maggi S, Reginster JY (2022) Intervention thresholds and diagnostic thresholds in the management of osteoporosis. Aging Clin Exp Res 34:3155–3157PubMedPubMedCentralCrossRef
4.
go back to reference Veronese N, Briot K, Guanabens N et al (2024) Recommendations for the optimal use of bone forming agents in osteoporosis. Aging Clin Exp Res 36:167PubMedPubMedCentralCrossRef
Veronese N, Briot K, Guanabens N et al (2024) Recommendations for the optimal use of bone forming agents in osteoporosis. Aging Clin Exp Res 36:167PubMedPubMedCentralCrossRef
5.
go back to reference McClung MR (2021) Role of bone-forming agents in the management of osteoporosis. Aging Clin Exp Res 33:775–791PubMedCrossRef
McClung MR (2021) Role of bone-forming agents in the management of osteoporosis. Aging Clin Exp Res 33:775–791PubMedCrossRef
6.
go back to reference Reginster J, Bianic F, Campbell R, Martin M, Williams SA, Fitzpatrick LA (2019) Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Osteoporos Int 30:1465–1473PubMedPubMedCentralCrossRef
Reginster J, Bianic F, Campbell R, Martin M, Williams SA, Fitzpatrick LA (2019) Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Osteoporos Int 30:1465–1473PubMedPubMedCentralCrossRef
7.
go back to reference Diez-Perez A, Marin F, Eriksen EF, Kendler DL, Krege JH, Delgado-Rodriguez M (2019) Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis. Bone 120:1–8PubMedCrossRef
Diez-Perez A, Marin F, Eriksen EF, Kendler DL, Krege JH, Delgado-Rodriguez M (2019) Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis. Bone 120:1–8PubMedCrossRef
8.
go back to reference Ouyang Y, Chen S, Wan T, Zheng G, Sun G (2021) The effects of teriparatide and bisphosphonates on new fractures in postmenopausal women with osteoporosis: a protocol for systematic review and meta-analysis. Medicine (Baltimore) 100:e24839PubMedCrossRef
Ouyang Y, Chen S, Wan T, Zheng G, Sun G (2021) The effects of teriparatide and bisphosphonates on new fractures in postmenopausal women with osteoporosis: a protocol for systematic review and meta-analysis. Medicine (Baltimore) 100:e24839PubMedCrossRef
9.
go back to reference Hong P, Liu R, Rai S, Liu J, Zhou Y, Zheng Y, Li J (2023) Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis. J Orthop Surg Res 18:116PubMedPubMedCentralCrossRef
Hong P, Liu R, Rai S, Liu J, Zhou Y, Zheng Y, Li J (2023) Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis. J Orthop Surg Res 18:116PubMedPubMedCentralCrossRef
10.
go back to reference Beaudart C, Demonceau C, Sabico S, Veronese N, Cooper C, Harvey N, Fuggle N, Bruyere O, Rizzoli R, Reginster JY (2023) Efficacy of osteoporosis pharmacological treatments in men: a systematic review and meta-analysis. Aging Clin Exp Res 35:1789–1806PubMedPubMedCentralCrossRef
Beaudart C, Demonceau C, Sabico S, Veronese N, Cooper C, Harvey N, Fuggle N, Bruyere O, Rizzoli R, Reginster JY (2023) Efficacy of osteoporosis pharmacological treatments in men: a systematic review and meta-analysis. Aging Clin Exp Res 35:1789–1806PubMedPubMedCentralCrossRef
11.
go back to reference Han YX, Mo YY, Wu HX et al (2024) Safety and efficacy of sequential treatments for postmenopausal osteoporosis: a network meta-analysis of randomised controlled trials. EClinicalMedicine 68:102425PubMedPubMedCentralCrossRef
Han YX, Mo YY, Wu HX et al (2024) Safety and efficacy of sequential treatments for postmenopausal osteoporosis: a network meta-analysis of randomised controlled trials. EClinicalMedicine 68:102425PubMedPubMedCentralCrossRef
12.
go back to reference Moon RJ, Reginster JY, Al-Daghri NM et al (2023) Real-world evidence: new opportunities for osteoporosis research. Recommendations from a working group from the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO). Osteoporos Int 34:1283–1299PubMedPubMedCentralCrossRef
Moon RJ, Reginster JY, Al-Daghri NM et al (2023) Real-world evidence: new opportunities for osteoporosis research. Recommendations from a working group from the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO). Osteoporos Int 34:1283–1299PubMedPubMedCentralCrossRef
13.
go back to reference Bernstein J, Weintraub S, Morris T, Ahn J (2019) Randomized controlled trials for geriatric hip fracture are rare and underpowered: a systematic review and a call for greater collaboration. J Bone Joint Surg Am 101:e132PubMedCrossRef
Bernstein J, Weintraub S, Morris T, Ahn J (2019) Randomized controlled trials for geriatric hip fracture are rare and underpowered: a systematic review and a call for greater collaboration. J Bone Joint Surg Am 101:e132PubMedCrossRef
14.
go back to reference Adami G, Gavioli I, Rossini M, Viapiana O, Orsolini G, Benini C, Bertoldo E, Fracassi E, Gatti D, Fassio A (2022) Real-life short-term effectiveness of anti-osteoporotic treatments: a longitudinal cohort study. Ther Adv Musculoskelet Dis 14:1759720X221105009PubMedPubMedCentralCrossRef
Adami G, Gavioli I, Rossini M, Viapiana O, Orsolini G, Benini C, Bertoldo E, Fracassi E, Gatti D, Fassio A (2022) Real-life short-term effectiveness of anti-osteoporotic treatments: a longitudinal cohort study. Ther Adv Musculoskelet Dis 14:1759720X221105009PubMedPubMedCentralCrossRef
15.
go back to reference Cosman F, Cooper C, Wang Y, Mitlak B, Varughese S, Williams SA (2022) Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: a US administrative claims database study. Osteoporos Int 33:1703–1714PubMedPubMedCentralCrossRef
Cosman F, Cooper C, Wang Y, Mitlak B, Varughese S, Williams SA (2022) Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: a US administrative claims database study. Osteoporos Int 33:1703–1714PubMedPubMedCentralCrossRef
16.
go back to reference Matsumoto T, Sone T, Soen S, Tanaka S, Yamashita A, Inoue T (2022) Abaloparatide increases lumbar spine and hip BMD in Japanese patients with osteoporosis: the phase 3 ACTIVE-J Study. J Clin Endocrinol Metab 107:e4222–e4231PubMedPubMedCentralCrossRef
Matsumoto T, Sone T, Soen S, Tanaka S, Yamashita A, Inoue T (2022) Abaloparatide increases lumbar spine and hip BMD in Japanese patients with osteoporosis: the phase 3 ACTIVE-J Study. J Clin Endocrinol Metab 107:e4222–e4231PubMedPubMedCentralCrossRef
17.
go back to reference Tabatabai L, Cosman F, Curtis JR et al (2024) Comparative effectiveness of abaloparatide and teriparatide in women 50 years of age and older: update of a real-world retrospective analysis. Endocr Pract 31:159–168PubMedCrossRef
Tabatabai L, Cosman F, Curtis JR et al (2024) Comparative effectiveness of abaloparatide and teriparatide in women 50 years of age and older: update of a real-world retrospective analysis. Endocr Pract 31:159–168PubMedCrossRef
18.
go back to reference Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162:777–784PubMedCrossRef
Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162:777–784PubMedCrossRef
19.
go back to reference Morrison A, Polisena J, Husereau D, Moulton K, Clark M, Fiander M, Mierzwinski-Urban M, Clifford T, Hutton B, Rabb D (2012) The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. Int J Technol Assess Health Care 28:138–144PubMedCrossRef
Morrison A, Polisena J, Husereau D, Moulton K, Clark M, Fiander M, Mierzwinski-Urban M, Clifford T, Hutton B, Rabb D (2012) The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. Int J Technol Assess Health Care 28:138–144PubMedCrossRef
20.
go back to reference Dobrescu AI, Nussbaumer-Streit B, Klerings I, Wagner G, Persad E, Sommer I, Herkner H, Gartlehner G (2021) Restricting evidence syntheses of interventions to English-language publications is a viable methodological shortcut for most medical topics: a systematic review. J Clin Epidemiol 137:209–217PubMedCrossRef
Dobrescu AI, Nussbaumer-Streit B, Klerings I, Wagner G, Persad E, Sommer I, Herkner H, Gartlehner G (2021) Restricting evidence syntheses of interventions to English-language publications is a viable methodological shortcut for most medical topics: a systematic review. J Clin Epidemiol 137:209–217PubMedCrossRef
21.
go back to reference Grey A, Reid IR (2006) Differences between the bisphosphonates for the prevention and treatment of osteoporosis. Ther Clin Risk Manag 2:77–86PubMedPubMedCentral
Grey A, Reid IR (2006) Differences between the bisphosphonates for the prevention and treatment of osteoporosis. Ther Clin Risk Manag 2:77–86PubMedPubMedCentral
22.
go back to reference Fujita T, Fukunaga M, Itabashi A, Tsutani K, Nakamura T (2014) Once-weekly injection of low-dose teriparatide (28.2 mug) reduced the risk of vertebral fracture in patients with primary osteoporosis. Calcif Tissue Int 94:170–175PubMedCrossRef
Fujita T, Fukunaga M, Itabashi A, Tsutani K, Nakamura T (2014) Once-weekly injection of low-dose teriparatide (28.2 mug) reduced the risk of vertebral fracture in patients with primary osteoporosis. Calcif Tissue Int 94:170–175PubMedCrossRef
23.
go back to reference Sterne JAC, Savovic J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898PubMedCrossRef
Sterne JAC, Savovic J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898PubMedCrossRef
24.
go back to reference Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A (2007) Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 26:53–77PubMedCrossRef
Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A (2007) Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 26:53–77PubMedCrossRef
25.
go back to reference Boytsov N, Zhang X, Sugihara T, Taylor K, Swindle R (2015) Osteoporotic fractures and associated hospitalizations among patients treated with teriparatide compared to a matched cohort of patients not treated with teriparatide. Curr Med Res Opin 31:1665–1675PubMedCrossRef
Boytsov N, Zhang X, Sugihara T, Taylor K, Swindle R (2015) Osteoporotic fractures and associated hospitalizations among patients treated with teriparatide compared to a matched cohort of patients not treated with teriparatide. Curr Med Res Opin 31:1665–1675PubMedCrossRef
26.
go back to reference Yusuf AA, Cummings SR, Watts NB, Feudjo MT, Sprafka JM, Zhou J, Guo H, Balasubramanian A, Cooper C (2018) Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women. Arch Osteoporos 13:33PubMedPubMedCentralCrossRef
Yusuf AA, Cummings SR, Watts NB, Feudjo MT, Sprafka JM, Zhou J, Guo H, Balasubramanian A, Cooper C (2018) Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women. Arch Osteoporos 13:33PubMedPubMedCentralCrossRef
27.
go back to reference Reynolds AW, Liu G, Kocis PT, Skowronski JN, Leslie DL, Fox EJ (2018) Comparison of osteoporosis pharmacotherapy fracture rates: analysis of a MarketScan((R)) claims database cohort. Int J Endocrinol Metab 16:e12104PubMedPubMedCentralCrossRef
Reynolds AW, Liu G, Kocis PT, Skowronski JN, Leslie DL, Fox EJ (2018) Comparison of osteoporosis pharmacotherapy fracture rates: analysis of a MarketScan((R)) claims database cohort. Int J Endocrinol Metab 16:e12104PubMedPubMedCentralCrossRef
28.
go back to reference O’Kelly J, Bartsch R, Kossack N, Borchert J, Pignot M, Hadji P (2022) Real-world effectiveness of osteoporosis treatments in Germany. Arch Osteoporos 17:119PubMedPubMedCentralCrossRef
O’Kelly J, Bartsch R, Kossack N, Borchert J, Pignot M, Hadji P (2022) Real-world effectiveness of osteoporosis treatments in Germany. Arch Osteoporos 17:119PubMedPubMedCentralCrossRef
29.
go back to reference Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRef
Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRef
30.
go back to reference Body JJ, Gaich GA, Scheele WH et al (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:4528–4535PubMedCrossRef
Body JJ, Gaich GA, Scheele WH et al (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:4528–4535PubMedCrossRef
31.
go back to reference Hadji P, Zanchetta JR, Russo L et al (2012) The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int 23:2141–2150PubMedCrossRef
Hadji P, Zanchetta JR, Russo L et al (2012) The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int 23:2141–2150PubMedCrossRef
32.
go back to reference Nakamura T, Sugimoto T, Nakano T et al (2012) Randomized Teriparatide [human parathyroid hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97:3097–3106PubMedCrossRef
Nakamura T, Sugimoto T, Nakano T et al (2012) Randomized Teriparatide [human parathyroid hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97:3097–3106PubMedCrossRef
33.
go back to reference Li Y, Xuan M, Wang B et al (2013) Comparison of parathyroid hormone (1–34) and elcatonin in postmenopausal women with osteoporosis: an 18-month randomized, multicenter controlled trial in China. Chin Med J (Engl) 126:457–463PubMedCrossRef
Li Y, Xuan M, Wang B et al (2013) Comparison of parathyroid hormone (1–34) and elcatonin in postmenopausal women with osteoporosis: an 18-month randomized, multicenter controlled trial in China. Chin Med J (Engl) 126:457–463PubMedCrossRef
34.
go back to reference Miller PD, Hattersley G, Riis BJ et al (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316:722–733PubMedCrossRef
Miller PD, Hattersley G, Riis BJ et al (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316:722–733PubMedCrossRef
35.
go back to reference Malouf-Sierra J, Tarantino U, Garcia-Hernandez PA et al (2017) Effect of teriparatide or risedronate in elderly patients with a recent pertrochanteric hip fracture: final results of a 78-week randomized clinical trial. J Bone Miner Res 32:1040–1051PubMedCrossRef
Malouf-Sierra J, Tarantino U, Garcia-Hernandez PA et al (2017) Effect of teriparatide or risedronate in elderly patients with a recent pertrochanteric hip fracture: final results of a 78-week randomized clinical trial. J Bone Miner Res 32:1040–1051PubMedCrossRef
36.
go back to reference Kendler DL, Marin F, Zerbini CAF et al (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391:230–240PubMedCrossRef
Kendler DL, Marin F, Zerbini CAF et al (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391:230–240PubMedCrossRef
37.
go back to reference Hagino H, Sugimoto T, Tanaka S, Sasaki K, Sone T, Nakamura T, Soen S, Mori S (2021) A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05. Osteoporos Int 32:2301–2311PubMedPubMedCentralCrossRef
Hagino H, Sugimoto T, Tanaka S, Sasaki K, Sone T, Nakamura T, Soen S, Mori S (2021) A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05. Osteoporos Int 32:2301–2311PubMedPubMedCentralCrossRef
38.
go back to reference Harrison J, Mozzicato P (2009) MedDRA®: the tale of a terminology: side effects of drugs essay. Side effects of drugs annual. Elsevier, pp xxxiii-xli
Harrison J, Mozzicato P (2009) MedDRA®: the tale of a terminology: side effects of drugs essay. Side effects of drugs annual. Elsevier, pp xxxiii-xli
39.
go back to reference Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F (1997) Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550–555PubMedCrossRef
Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F (1997) Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550–555PubMedCrossRef
40.
go back to reference Sing CW, Lin TC, Bartholomew S et al (2021) Global epidemiology of hip fractures: a study protocol using a common analytical platform among multiple countries. BMJ Open 11:e047258PubMedPubMedCentralCrossRef
Sing CW, Lin TC, Bartholomew S et al (2021) Global epidemiology of hip fractures: a study protocol using a common analytical platform among multiple countries. BMJ Open 11:e047258PubMedPubMedCentralCrossRef
41.
go back to reference LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES (2022) The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 33:2049–2102PubMedPubMedCentralCrossRef
LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES (2022) The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 33:2049–2102PubMedPubMedCentralCrossRef
42.
go back to reference Bone HG, Cosman F, Miller PD et al (2018) ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab 103:2949–2957PubMedPubMedCentralCrossRef
Bone HG, Cosman F, Miller PD et al (2018) ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab 103:2949–2957PubMedPubMedCentralCrossRef
43.
go back to reference Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ (2016) Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology 157:141–149PubMedCrossRef
Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ (2016) Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology 157:141–149PubMedCrossRef
44.
go back to reference Khosla S, Hofbauer LC (2017) Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol 5:898–907PubMedPubMedCentralCrossRef
Khosla S, Hofbauer LC (2017) Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol 5:898–907PubMedPubMedCentralCrossRef
45.
go back to reference Cheloha RW, Gellman SH, Vilardaga JP, Gardella TJ (2015) PTH receptor-1 signalling-mechanistic insights and therapeutic prospects. Nat Rev Endocrinol 11:712–724PubMedPubMedCentralCrossRef
Cheloha RW, Gellman SH, Vilardaga JP, Gardella TJ (2015) PTH receptor-1 signalling-mechanistic insights and therapeutic prospects. Nat Rev Endocrinol 11:712–724PubMedPubMedCentralCrossRef
46.
go back to reference Tabacco G, Bilezikian JP (2019) Osteoanabolic and dual action drugs. Br J Clin Pharmacol 85:1084–1094PubMedPubMedCentralCrossRef
Tabacco G, Bilezikian JP (2019) Osteoanabolic and dual action drugs. Br J Clin Pharmacol 85:1084–1094PubMedPubMedCentralCrossRef
47.
go back to reference Winzenrieth R, Ominsky MS, Wang Y, Humbert L, Weiss RJ (2021) Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modeling. Osteoporos Int 32:575–583PubMedPubMedCentralCrossRef
Winzenrieth R, Ominsky MS, Wang Y, Humbert L, Weiss RJ (2021) Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modeling. Osteoporos Int 32:575–583PubMedPubMedCentralCrossRef
48.
go back to reference Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ (2006) Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 54:782–789PubMedCrossRef
Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ (2006) Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 54:782–789PubMedCrossRef
49.
go back to reference McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340PubMedCrossRef
McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340PubMedCrossRef
50.
go back to reference Li M, Ge Z, Zhang B, Sun L, Wang Z, Zou T, Chen Q (2024) Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials. Arch Osteoporos 19:89PubMedPubMedCentralCrossRef
Li M, Ge Z, Zhang B, Sun L, Wang Z, Zou T, Chen Q (2024) Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials. Arch Osteoporos 19:89PubMedPubMedCentralCrossRef
51.
go back to reference Jin YZ, Lee JH, Xu B, Cho M (2019) Effect of medications on prevention of secondary osteoporotic vertebral compression fracture, non-vertebral fracture, and discontinuation due to adverse events: a meta-analysis of randomized controlled trials. BMC Musculoskelet Disord 20:399PubMedPubMedCentralCrossRef
Jin YZ, Lee JH, Xu B, Cho M (2019) Effect of medications on prevention of secondary osteoporotic vertebral compression fracture, non-vertebral fracture, and discontinuation due to adverse events: a meta-analysis of randomized controlled trials. BMC Musculoskelet Disord 20:399PubMedPubMedCentralCrossRef
52.
go back to reference Masuda S, Fukasawa T, Matsuda S, Yoshida S, Kawakami K (2024) Comparative effectiveness and cardiovascular safety of romosozumab versus teriparatide in patients with osteoporosis: a population-based cohort study. Osteoporos Int 35:2165–2174PubMedCrossRef
Masuda S, Fukasawa T, Matsuda S, Yoshida S, Kawakami K (2024) Comparative effectiveness and cardiovascular safety of romosozumab versus teriparatide in patients with osteoporosis: a population-based cohort study. Osteoporos Int 35:2165–2174PubMedCrossRef
53.
go back to reference Yang XC, Deng ZH, Wen T, Luo W, Xiao WF, Zhao RB, Li YS (2016) Network meta-analysis of pharmacological agents for osteoporosis treatment and fracture prevention. Cell Physiol Biochem 40:781–795PubMedCrossRef
Yang XC, Deng ZH, Wen T, Luo W, Xiao WF, Zhao RB, Li YS (2016) Network meta-analysis of pharmacological agents for osteoporosis treatment and fracture prevention. Cell Physiol Biochem 40:781–795PubMedCrossRef
54.
go back to reference Migliorini F, Maffulli N, Colarossi G, Eschweiler J, Tingart M, Betsch M (2021) Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis. J Orthop Surg Res 16:533PubMedPubMedCentralCrossRef
Migliorini F, Maffulli N, Colarossi G, Eschweiler J, Tingart M, Betsch M (2021) Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis. J Orthop Surg Res 16:533PubMedPubMedCentralCrossRef
55.
go back to reference Kanis JA, Harvey NC, McCloskey E et al (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 31:1–12PubMedCrossRef
Kanis JA, Harvey NC, McCloskey E et al (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 31:1–12PubMedCrossRef
56.
go back to reference Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O, Osteoarthritis, the Committees of Scientific A, National Societies of the International Osteoporosis (2019) Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcif Tissue Int 104:235–238PubMedPubMedCentralCrossRef
Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O, Osteoarthritis, the Committees of Scientific A, National Societies of the International Osteoporosis (2019) Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcif Tissue Int 104:235–238PubMedPubMedCentralCrossRef
57.
go back to reference Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O, Osteoarthritis, the Committees of Scientific A, National Societies of the International Osteoporosis F (2019) Executive summary of European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Aging Clin Exp Res 31:15–17PubMedCrossRef
Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O, Osteoarthritis, the Committees of Scientific A, National Societies of the International Osteoporosis F (2019) Executive summary of European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Aging Clin Exp Res 31:15–17PubMedCrossRef
58.
go back to reference Camacho PM, Petak SM, Binkley N et al (2020) American association of Clinical Endocrinologists/American College of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis- 2020 update executive summary. Endocr Pract 26:564–570PubMedCrossRef
Camacho PM, Petak SM, Binkley N et al (2020) American association of Clinical Endocrinologists/American College of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis- 2020 update executive summary. Endocr Pract 26:564–570PubMedCrossRef
59.
go back to reference Gregson CL, Armstrong DJ, Bowden J et al (2022) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 17:58PubMedPubMedCentralCrossRef
Gregson CL, Armstrong DJ, Bowden J et al (2022) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 17:58PubMedPubMedCentralCrossRef
60.
go back to reference Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol Pathol 30:312–321PubMedCrossRef
Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol Pathol 30:312–321PubMedCrossRef
61.
go back to reference European Medicines Agency (2024) Summary of Product Characteristics — Eladynos. https://www.ema.europa.eu/en/documents/product-information/eladynos-epar-product-information_en.pdf Accessed 21 Oct 2024
European Medicines Agency (2024) Summary of Product Characteristics — Eladynos. https://www.ema.europa.eu/en/documents/product-information/eladynos-epar-product-information_en.pdf Accessed 21 Oct 2024
62.
go back to reference European Medicines Agency (2024) Summary of Product Characteristics — Forsteo. https://www.ema.europa.eu/en/documents/product-information/forsteo-epar-product-information_en.pdf Accessed 30 Oct 2024
European Medicines Agency (2024) Summary of Product Characteristics — Forsteo. https://www.ema.europa.eu/en/documents/product-information/forsteo-epar-product-information_en.pdf Accessed 30 Oct 2024
63.
go back to reference Food and Drug Administration (2024) Prescribing Information — TYMLOS. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208743lbl.pdf Accessed 30 Oct 2024
Food and Drug Administration (2024) Prescribing Information — TYMLOS. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208743lbl.pdf Accessed 30 Oct 2024
64.
go back to reference Food and Drug Administration (2024) Prescribing Information — FORSTEO. https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21318_forteo_lbl.pdf Accessed 30 Oct 2024
Food and Drug Administration (2024) Prescribing Information — FORSTEO. https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21318_forteo_lbl.pdf Accessed 30 Oct 2024
65.
go back to reference Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M (2004) Bone neoplasms in F344 rats given teriparatide [rhPTH(1–34)] are dependent on duration of treatment and dose. Toxicol Pathol 32:426–438PubMedCrossRef
Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M (2004) Bone neoplasms in F344 rats given teriparatide [rhPTH(1–34)] are dependent on duration of treatment and dose. Toxicol Pathol 32:426–438PubMedCrossRef
66.
go back to reference Abdulelah AA, Haddad BI, Alhajahjeh AA, AlQirem LM, El-Amayreh L (2023) The risk of developing osteosarcoma after teriparatide use: a systematic review. Orthop Res Rev 15:191–198PubMedPubMedCentral
Abdulelah AA, Haddad BI, Alhajahjeh AA, AlQirem LM, El-Amayreh L (2023) The risk of developing osteosarcoma after teriparatide use: a systematic review. Orthop Res Rev 15:191–198PubMedPubMedCentral
67.
go back to reference European Medicines Agency (2024) Forsteo — EPAR Procedural steps taken and scientific information after authorisation. https://www.ema.europa.eu/en/documents/procedural-steps-after/forsteo-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf Accessed 19 Nov 2024
European Medicines Agency (2024) Forsteo — EPAR Procedural steps taken and scientific information after authorisation. https://www.ema.europa.eu/en/documents/procedural-steps-after/forsteo-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf Accessed 19 Nov 2024
68.
go back to reference Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, Masica D (2012) The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res 27:2429–2437PubMedCrossRef
Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, Masica D (2012) The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res 27:2429–2437PubMedCrossRef
69.
go back to reference Gilsenan A, Midkiff K, Harris D, Kellier-Steele N, McSorley D, Andrews EB (2021) Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study. J Bone Miner Res 36:244–251PubMedCrossRef
Gilsenan A, Midkiff K, Harris D, Kellier-Steele N, McSorley D, Andrews EB (2021) Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study. J Bone Miner Res 36:244–251PubMedCrossRef
70.
go back to reference Sherpa C, Shrestha BC, Nallala D, Gabriely I (2021) Hypercalcemia in a patient treated with abaloparatide. J Endocrine Soc 5:A196–A197CrossRef
Sherpa C, Shrestha BC, Nallala D, Gabriely I (2021) Hypercalcemia in a patient treated with abaloparatide. J Endocrine Soc 5:A196–A197CrossRef
71.
go back to reference Seeto AH, Tadrous M, Gebre AK, Lewis JR, Fink HA, Ebeling PR, Rodriguez AJ (2023) Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: a systematic review and Bayesian network meta-analysis. Bone 167:116610PubMedCrossRef
Seeto AH, Tadrous M, Gebre AK, Lewis JR, Fink HA, Ebeling PR, Rodriguez AJ (2023) Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: a systematic review and Bayesian network meta-analysis. Bone 167:116610PubMedCrossRef
Metadata
- Title
- PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis
- Authors
-
Charlotte Beaudart
Nicola Veronese
Jonathan Douxfils
Jotheeswaran Amuthavalli Thiyagarajan
Francesco Bolzetta
Paolo Albanese
Gianpaolo Voltan
Majed Alokail
Nicholas C. Harvey
Nicholas R. Fuggle
Olivier Bruyère
René Rizzoli
Jean-Yves Reginster
- Publication date
- 06-03-2025
- Publisher
- Springer London
- Published in
-
Osteoporosis International
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965 - DOI
- https://doi.org/10.1007/s00198-025-07440-1